Literature DB >> 15582984

Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.

Bernd Jahrsdörfer1, James E Wooldridge, Sue E Blackwell, Christiana M Taylor, Thomas S Griffith, Brian K Link, George J Weiner.   

Abstract

Immunostimulatory oligodeoxynucleotides (IS ODN) can mediate a number of immunologic effects. We previously demonstrated that treatment of B cell chronic lymphocytic leukemia (B-CLL) cells with one class of IS ODN, CpG ODN, alters their phenotype and increases their immunogenicity. Here, we demonstrate that in contrast to the classic understanding of CpG ODN as inhibitors of B cell apoptosis, IS ODN including CpG ODN induce apoptosis in B-CLL cells. It is important that these changes are seen not only with CpG ODN but with ODN that lack the classical CpG motif. B-CLL cells from 20 subjects were treated in vitro with IS ODN for up to 7 days. IS ODN treatment resulted in increased numbers of apoptotic cells in 13 out of 20 B-CLL samples. IS ODN enhanced apoptosis in samples with 13q deletion as a single aberration and had a heterogeneous effect on apoptosis in samples with other aberrations including 17p deletion, 11q deletion, or trisomy 12. Induction of apoptosis did not correlate with expression of the CpG ODN receptor Toll-like receptor 9. Apoptosis was dependent on the activation of caspases and was accompanied by up-regulation of CD95/Fas and its ligand. We conclude that IS ODN including CpG ODN can induce apoptosis of most B-CLL samples. The ability of IS ODN to induce apoptosis differs based on cytogenetic status. Up-regulation of CD95/Fas may play a role in IS ODN-induced apoptosis of B-CLL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15582984     DOI: 10.1189/jlb.0604373

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  21 in total

1.  Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.

Authors:  Xueqing Liang; E Ashley Moseman; Michael A Farrar; Veronika Bachanova; Daniel J Weisdorf; Bruce R Blazar; Wei Chen
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

Review 2.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

3.  Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia.

Authors:  Clive S Zent; Brian J Smith; Zuhair K Ballas; James E Wooldridge; Brian K Link; Timothy G Call; Tait D Shanafelt; Deborah A Bowen; Neil E Kay; Thomas E Witzig; George J Weiner
Journal:  Leuk Lymphoma       Date:  2011-09-19

Review 4.  Toll-like receptors: lessons to learn from normal and malignant human B cells.

Authors:  David Chiron; Isabelle Bekeredjian-Ding; Catherine Pellat-Deceunynck; Régis Bataille; Gaëtan Jego
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

5.  Autophagy links pattern recognition receptors to tumor cell apoptosis.

Authors:  Jörg Vollmer
Journal:  Mol Ther       Date:  2009-11       Impact factor: 11.454

6.  Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis.

Authors:  Kristine L Holm; Randi L Indrevaer; June Helen Myklebust; Arne Kolstad; Jan Øivind Moskaug; Elin H Naderi; Heidi K Blomhoff
Journal:  Immunology       Date:  2016-07-25       Impact factor: 7.397

7.  B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation.

Authors:  Bernd Jahrsdörfer; Sue E Blackwell; James E Wooldridge; Jian Huang; Melinda W Andreski; Laura S Jacobus; Christiana M Taylor; George J Weiner
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

8.  Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.

Authors:  Rashmi Gupta; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

9.  TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.

Authors:  Patricia K A Mongini; Rashmi Gupta; Erin Boyle; Jennifer Nieto; Hyunjoo Lee; Joanna Stein; Jela Bandovic; Tatjana Stankovic; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

10.  B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.

Authors:  Magdalena Hagn; Sue E Blackwell; Thamara Beyer; Verena Ebel; Dorit Fabricius; Stefanie Lindner; Stefan Stilgenbauer; Thomas Simmet; Constantine Tam; Paul Neeson; Joseph A Trapani; Hubert Schrezenmeier; George J Weiner; Bernd Jahrsdörfer
Journal:  Int Immunol       Date:  2014-02-04       Impact factor: 4.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.